Further, we demonstrated a relationship between NRF2 function, HER2/HER3 signalling, ROS generation, and the sensitisation of ovarian cancer cells to the killing effects of the targeted therapeutics, trastuzumab, pertuzumab, or their combination [22, 24]. Here, NFE2L2 is linked to ovarian cancer.